Loading…
HDL-like discs for assaying membrane proteins in drug discovery
To broaden the use of the recombinant high-density lipoprotein (rHDL) approach to the characterization of lead compounds, we investigated the pharmacology of the human beta-2-adrenoceptor in nanolipid bilayers (rHDL) with a broad set of beta-adrenoceptor antagonists. To that end, we developed a homo...
Saved in:
Published in: | Biophysical chemistry 2012-05, Vol.165-166, p.56-61 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | To broaden the use of the recombinant high-density lipoprotein (rHDL) approach to the characterization of lead compounds, we investigated the pharmacology of the human beta-2-adrenoceptor in nanolipid bilayers (rHDL) with a broad set of beta-adrenoceptor antagonists. To that end, we developed a homogeneous copper-chelate scintillation proximity binding assay (SPA) in order to compare receptor-ligand binding affinities before and after reconstitution into rHDLs. Our results clearly show that the beta-2-adrenoceptor reconstituted in rHDLs display the same pharmacology as that in cell membranes and that rHDLs can be used not only to measure affinities for a range of ligands but also to study binding kinetics.
[Display omitted]
► A SPA-based homogeneous assay allowing the study of ligand binding to the β2AR. ► β2AR has the same pharmacology in rHDLs than in cell membranes for a set of antagonists. ► Antagonist binding is right-shifted to lower affinities for the solubilized receptor. ► rHDL-like discs can be used for compound screening and lead optimization. |
---|---|
ISSN: | 0301-4622 1873-4200 |
DOI: | 10.1016/j.bpc.2012.03.005 |